# A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer

Source: https://onco.cc/trials/nct06184035/  
OnCo record `nct06184035` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of [177Lu]Lu-SN201 in advanced solid tumours, run by Spago Nanomedical AB, now recruiting.

## Summary

A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer is a phase 1/2 interventional study registered as NCT06184035 by Spago Nanomedical AB, with 90 participants planned, started 2023-12-06 and due to reach its primary completion in 2027-12-01. Interventions recorded: [177Lu]Lu-SN201.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06184035
- Phase: 1/2
- Setting: Ph I/IIa Escalation/Expansion FIH, Open, Multi Center, Single Arm Study Evaluating Safety, Dosimetry and Early Efficacy of 177Lu-SN201 in Progressive/Treatment-refractory, Locally Advanced, Unresectable Metastatic or Recurrent Solid Tumors
- Sponsor: Spago Nanomedical AB
- Enrolled: 90

## Sources

- ClinicalTrials.gov NCT06184035: https://clinicaltrials.gov/study/NCT06184035

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct06184035.json